Variant
KRAS A146
CI-VAR-00000056Explore in graph →CIViC 2979
Curated evidence
Evidence by cancer (2 items)
Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 34820593
- Run
- ING-CIVIC-20260908-000001
| Molecular profile | Therapy | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| Malignant Colorectal Neoplasm2 | ||||||||
| KRAS A146 | (prognostic) | Prognostic | B | Supports Poor Outcome | 2 | submitted | EID10656A study of 419 patients with liver metastases of colorectal cancer identified 12 with A146 mutations. Compared to KRAS G12 tumors, patients with A146 positive tumors exhibited higher ctDNA levels. Pat… (full text at CIViC) PMID 34820593 · van 't Erve et al., 2021 · Open in CIViC | civic |
| KRAS A146 | Cetuximab + ChemotherapyCombination | Predictive | B | Does Not Support Resistance | 3 | accepted | EID3939This was a retrospective study of 605 patients with metastatic, chemotherapy refractory colorectal cancer treated with cetuximab + chemotherapy. Patients harboring KRAS codon 146 mutant tumors (n=11) … (full text at CIViC) PMID 20619739 · De Roock et al., 2010 · | |
ClinVar
Clinical significance (0)
ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.
Data not yet available